Related Experiment Video
Updated: Aug 19, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury
Maja Milovanceva-Popovska1, Uta Kunter, Tammo Ostendorf
1Division of Nephrology, University of Aachen, Aachen, Germany.
Background:
Cyclin-dependent kinase (CDK) inhibition is a new therapeutic approach to proliferative glomerulonephritides. CDK2 is required for G(1)/S transition and DNA synthesis and is inhibited by CYC202 (R-roscovitine). Since podocytes express CDK2 in nephritis and since loss of podocytes contributes to glomerulosclerosis, the rationale of the present study was to test whether CDK2 inhibition is safe in instances of podocyte injury.
Methods:
Rats with passive Heymann nephritis, a model of membranous glomerulonephritis, were treated (day 3 to 30) with vehicle, low (25 mg/kg/day), or high (50 mg/kg/day) doses of CYC202.
Results:
On day 27, blood pressure was normal in nephritic controls and was dose-dependently reduced by CYC202. Urinary albumin excretion did not differ between the groups on days 9, 16, 23, and 30. To investigate podocyte injury, we assessed the glomerular de novo expression of desmin, which was markedly up-regulated in almost all passive Heymann nephritis glomeruli but was not significantly different between the three groups. No tubulointerstitial de novo expression of desmin or alpha-smooth muscle actin (alpha-SMA), or tubulointerstitial monocyte/macrophage infiltration was noted in any group. Biologic activity of CYC202 was evident in the form of a dose-dependent decrease in the number of glomerular and tubulointerstitial mitotic figures as compared to vehicle alone. Glomerular immunostaining for cyclin D1, a marker for G(0) to G(1) transition, was significantly decreased in CYC202 treated groups at day 9.
Conclusion:
Whereas inhibition of CDKs by CYC202 reduced intrarenal cell proliferation in passive Heymann nephritis it did not aggravate podocyte damage, suggesting that this novel therapeutic approach is safe in renal diseases characterized by podocyte injury.
Insights
Cyclin-dependent kinase (CDK) inhibition using CYC202 safely reduced kidney cell proliferation in a nephritis model. This approach did not worsen podocyte injury, suggesting potential for treating proliferative glomerulonephritis.
Area of Science:
- Nephrology
- Pharmacology
- Cell Biology
Background:
- Proliferative glomerulonephritides are kidney diseases characterized by cell proliferation.
- Cyclin-dependent kinases (CDKs) regulate cell cycle progression, making them therapeutic targets.
- CDK2, crucial for DNA synthesis, is inhibited by CYC202 (R-roscovitine).
Purpose of the Study:
- To evaluate the safety and efficacy of CDK2 inhibition with CYC202 in a rat model of membranous glomerulonephritis.
- To determine if CYC202 treatment exacerbates podocyte injury, a key factor in glomerulosclerosis.
Main Methods:
- Rats with passive Heymann nephritis were treated with vehicle or varying doses of CYC202.
- Blood pressure and urinary albumin excretion were monitored.
- Podocyte injury markers (desmin, alpha-SMA) and cell proliferation (mitotic figures, cyclin D1) were assessed.
Main Results:
- CYC202 reduced blood pressure dose-dependently but did not alter albuminuria.
- No increased podocyte injury or tubulointerstitial inflammation was observed.
- CYC202 significantly decreased intrarenal mitotic figures and glomerular cyclin D1 expression.
Conclusions:
- CDK2 inhibition with CYC202 reduces intrarenal cell proliferation in experimental nephritis.
- This therapeutic strategy appears safe and does not aggravate podocyte damage.
- CDK inhibition is a promising approach for proliferative renal diseases involving podocyte injury.
